

August 13, 2016

**Bombay Stock Exchange Limited
Corporate Relationship Department
1st floor, New Trading Ring
Rotunda Building, P J Towers
Dalal Street, Fort
Mumbai - 400 001**

Sub: Press Release

Dear Sir/Madam,

Please find enclosed the Press Release issued in connection with Unaudited Financial Results of the Company for the quarter ended June 30, 2016.

Kindly take it on your records.

Thanking you,

Yours faithfully,



L Chandrasekar
Executive V P – Finance & Secretary.

Encl.: a/a



BSE: 524372 NSE: ORCHIDPHAR Bloomberg: OCP@IN Reuters: ORCD.BO

Q1 FY17 Earnings

Chennai, India – Aug 13, 2016

Orchid Pharma registers turnover of Rs 190.9 crore in Q1 FY17, EBITDA of Rs 22.3 crore.

Financial highlights for Quarter ended June 30, 2016 (Q1 FY17) – Standalone

- Revenue of Rs 190.9 crore (US\$ 28.1 million) in the quarter ended June 30, 2016 (Q1 FY17) as compared to Rs 256.3 crore (US\$ 37.7 million) registered during the quarter ended June 30, 2015 (Q1 FY15).
- EBITDA of Rs 22.3 crore (US\$ 3.3 million) in the quarter ended June 30, 2016 as compared to Rs 59.4 crore (US\$ 8.7 million) in the quarter ended June 30, 2015.
- At the net level, the company registered a loss of Rs 166.3 crore (US\$ 24.5 million) during the quarter ended June 30, 2016 as compared to a loss of Rs 47.6 crore (US\$ 7.0 million) for the corresponding quarter ended June 30, 2015.

*** 1 US\$ = Rs 68.00**

From the Managing Director

“The reduced turnover is on account of product mix and capacity utilization. However, with the support of the bankers, our customers and the proposed launch of new products in FY 2016-17, we are confident of improving the volumes and profitability in the ensuing quarters” said Mr K Raghavendra Rao, Managing Director, Orchid Pharma Ltd.

For ORCHID PHARMA LTD.


Executive VP - Finance & Secretary

‘Orchid Towers’, #313, Valluvar Kottam High Road, Nungambakkam, Chennai 600 034 INDIA